Menu Search
Equities

Geron Corp

  • Add to watchlist
  • Add to portfolio
  • Add an alert
0IV3:LSE

Geron Corp

Actions
  • Price (USD)1.55
  • Today's Change0.055 / 3.69%
  • Shares traded53.34k
  • 1 Year change-48.15%
  • Beta0.5995
Data delayed at least 20 minutes, as of Feb 06 2026 19:07 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Geron Corporation is a commercial-stage biopharmaceutical company. The Company develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. It is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.

  • Revenue in USD (TTM)183.40m
  • Net income in USD-79.99m
  • Incorporated1990
  • Employees229.00
  • Location
    Geron Corp919 East Hillsdale Boulevard, Suite 250FOSTER CITY 94404United StatesUSA
  • Phone+1 (650) 473-7700
  • Fax+1 (302) 655-5049
  • Websitehttps://www.geron.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.